missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Mouse TRAM/TICAM2 Antibody, R&D Systems™

Rat Monoclonal Antibody
Brand: R&D Systems MAB43481
This item is not returnable.
View return policy
Description
TRAM/TICAM2 Monoclonal specifically detects TRAM/TICAM2 in Mouse samples. It is validated for Immunocytochemistry.
Specifications
| TRAM/TICAM2 | |
| Monoclonal | |
| LYOPH | |
| Immunocytochemistry 8-25 ug/mL | |
| Q8BJQ4 | |
| TICAM2 | |
| E. coli-derived recombinant mouse TRAM/TICAM2 Met1-Ala232 Accession # Q8BJQ4 | |
| 100 μg | |
| Primary | |
| Detects mouse TRAM/TICAM2 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) TRAM or rhTRIF is observed. | |
| Mouse | |
| Purified |
| Immunocytochemistry | |
| 757712 | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
| MGC129876, MGC129877, Putative NF-kappa-B-activating protein 502, TICAM2, TICAM-2TIR domain-containing adapter molecule 2, TIRAP3, TIRP, TIRPcytoplasmic adaptor, toll/interleukin-1 receptor (TIR) domain-containing adapter protein, Toll/interleukin-1 receptor domain-containing protein, toll-like receptor adaptor molecule 2, Toll-like receptor adaptor protein 3, TRAMNF-kappa-B-activating protein 502, Trif, TRIF-related adapter molecule, TRIF-related adaptor molecule | |
| Rat | |
| Protein A or G purified from hybridoma culture supernatant | |
| RUO | |
| 353376 | |
| Sterile PBS to a final concentration of 0.5 mg/mL. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
| IgG2b |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction